Selank vs Semax for Anxiety: A Subjective Comparison That Tracking Can Actually Resolve
Selank and semax come up together so often in peptide forums that they tend to be discussed as a pair, almost as a single decision: pick one, run a cycle, see what happens. Both are short synthetic peptides developed at the Russian Academy of Medical Sciences, both are administered intranasally in the most common protocols, and both are described in the user-facing literature with overlapping vocabulary — "anxiolytic," "nootropic," "mood-supporting." That overlap is misleading. The compounds have different parent molecules, different mechanisms of action in the brain, and noticeably different subjective profiles in practice. The reason most side-by-side comparisons never reach a clear answer is not that the difference is small. It is that the dose logs underneath the comparison rarely contain the fields that would let you read it.
Different parents, different mechanisms
Selank is a synthetic analog of tuftsin, a four-residue immunomodulating peptide derived from the Fc fragment of immunoglobulin G. The selank molecule extends the tuftsin core with three additional residues that improve metabolic stability, and the resulting peptide acts on multiple systems — GABAergic, serotonergic, and on neuropeptide Y signalling — in ways that read as anxiolytic and mildly mood-stabilising in the published Russian work. Semax, by contrast, is a fragment analog of adrenocorticotropic hormone (ACTH 4–10), modified at the C-terminus to remove the corticotropic activity while retaining the central nervous system effects. The semax mechanism centres on increasing brain-derived neurotrophic factor and on modulating dopaminergic and serotonergic tone, and the user-facing description tends toward "stimulating, focus-promoting, attention-supporting" rather than "calming."
The practical implication is that the two peptides are not interchangeable approaches to the same problem. If your reason for running either is generalised baseline anxiety, selank is the closer match to the published profile. If your reason is task-engagement difficulty, low motivation, or attentional fatigue, semax is the closer match. Pick the wrong one for your actual target and the cycle will read as "didn't do much" even when the compound is performing as designed. That mismatch is the most common reason side-by-side comparisons fail to find a difference.
Onset and duration: very different curves
The most reliable way to tell which peptide you are actually feeling is the time course. Both are short-acting on a single dose, but the shapes are not the same:
- Selank tends to come on slowly and build over the first three to five days of consistent dosing. The single-dose effect on day one is often mild or absent; the cumulative effect by the end of week one is usually unambiguous. Users who try a single spray and conclude nothing happened are reading the curve at the wrong point.
- Semax is closer to a same-day compound. The subjective effect, when present, tends to be perceptible within the first 30 to 90 minutes after intranasal dosing and to fade by the end of the day. Cumulative effects on focus and motivation exist but are layered on top of a clear acute response.
If you log a dose and a baseline-anxiety score the same morning and the same evening, selank cycles will show the change as a slow downward drift over a week or two. Semax cycles will show same-day deltas on dose days. Pooling both into one "did the peptide help" question hides exactly the information that distinguishes them.
Why most comparisons end up inconclusive
The forums are full of write-ups that go: "ran selank for two weeks, then semax for two weeks, both seemed about the same, can't tell what the fuss is." The standard reasons this happens:
- No baseline. Two weeks of self-rated anxiety logged before either cycle started is the comparator. Without it, the cycle is being compared to memory, which always loses to recency.
- Wrong scale resolution. A binary "did it help yes/no" hides the gradient. A 0–10 scale logged at the same time of day, twice a day, captures the curve.
- Confounded targets. Logging "mood" alone collapses the distinction between anxiolysis and motivation. Splitting the log into a calm/agitated axis and an engaged/flat axis lets the two compounds register on different axes.
- Insufficient washout. Going straight from selank to semax with no washout muddies the attribution. A two-week clean period between the two cycles lets you read each on its own.
- Dosing irregularity. Intranasal dosing is easy to skip, easy to mistime, and very easy to deliver inconsistently between nostrils. A protocol logged as "twice daily" but actually run as "whenever I remember" produces noise that swamps any signal.
What to log for a real comparison
The fields that turn this from an impression into a comparison:
- Pre-cycle baseline. Twice-daily ratings on two axes — calm/agitated and engaged/flat — for at least one to two weeks before the first cycle.
- Dose, time, and side. Intranasal sprays vary; logging which nostril, what dose, and at what clock time turns the protocol from approximate to comparable.
- Same-day vs cumulative scoring. One score within two hours of the dose, one score at end of day. The pair captures both the acute window and the carry-over.
- Sleep, caffeine, training. All three move both axes meaningfully. Annotating them in the same log is what lets you separate compound effect from lifestyle confound.
- Washout. A two-week peptide-free period between the two cycles, with the same baseline tracking running through it. The washout is where you re-establish the comparator and stop selank's slow tail from contaminating the start of the semax cycle.
- Cycle length. Both compounds are typically run for two to four weeks. The cycle-length question generally is covered in the peptide cycle length guide.
What the data does not say
The published clinical literature on both peptides is mostly Russian-language and substantially older than the Western reader-facing descriptions imply. The trial sizes are modest, replication outside the original research groups is limited, and direct head-to-head selank-versus-semax comparisons are essentially absent. The mechanistic distinction described above is reasonably well grounded in the parent-molecule pharmacology; the magnitude of the effect in any given individual is not well predicted by the available data. Long-term safety information for repeated cycles in healthy users is similarly thin. None of this is medical advice; it is a description of why the two compounds register so differently in careful logs and so similarly in casual ones.
The practical summary
Selank and semax are not two flavours of the same idea. Selank descends from tuftsin and reads as a slow-onset anxiolytic that rewards a week or more of consistent dosing. Semax descends from ACTH 4–10 and reads as a same-day focus and motivation compound with a clear acute curve. Comparing them by impression collapses the distinction; comparing them with a two-axis baseline, same-time daily ratings, an annotated stack, and a real washout is what makes the difference visible. The compounds are different. The logs are usually what fail to show it.